Chronic Hepatitis B Therapeutics
1. Baraclude patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5206244 (Pediatric) | BRISTOL MYERS | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Aug, 2015
(10 years ago) | |
| US5206244 | BRISTOL MYERS | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
Feb, 2015
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-127) | Oct 15, 2013 |
| New Patient Population(NPP) | Oct 12, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2017 |
Drugs and Companies using ENTECAVIR ingredient
Market Authorisation Date: 29 March, 2005
Dosage: TABLET; SOLUTION
How can I launch a generic of BARACLUDE before it's drug patent expiration?
More Information on Dosage
BARACLUDE family patents
2. Hepsera patent expiration
Treatment: Therapy in chronic hepatitis b virus infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5663159 | GILEAD | Prodrugs of phosphonates |
Sep, 2014
(11 years ago) | |
| US6451340 | GILEAD | Nucleotide analog compositions |
Jul, 2018
(7 years ago) | |
Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient
Market Authorisation Date: 20 September, 2002
Dosage: TABLET
How can I launch a generic of HEPSERA before it's drug patent expiration?
More Information on Dosage
HEPSERA family patents
3. Tyzeka patent
expiration
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| US6569837 | NOVARTIS | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct, 2020
(5 years ago) | |
| US7795238 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6566344 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6444652 | NOVARTIS | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US6395716 | NOVARTIS | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug, 2019
(6 years ago) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2011 |
| M(M-124) | Jan 28, 2016 |
Drugs and Companies using TELBIVUDINE ingredient
NCE-1 date: 25 October, 2010
Market Authorisation Date: 25 October, 2006
Dosage: TABLET; SOLUTION
More Information on Dosage
TYZEKA family patents
4. Viread patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents; Treatment of hiv; Treatment of chronic hepatitis b
VIREAD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(8 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(8 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(8 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(8 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(8 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-569) | Aug 11, 2011 |
| New Patient Population(NPP) | Aug 16, 2015 |
| Pediatric Exclusivity(PED) | Sep 24, 2017 |
| M(M-95) | Oct 01, 2013 |
| New Dosage Form(NDF) | Jan 18, 2015 |
| M(M-128) | Jul 24, 2016 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
Drugs and Companies using TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 18 January, 2012
Dosage: POWDER; TABLET
How can I launch a generic of VIREAD before it's drug patent expiration?
More Information on Dosage
VIREAD family patents